Behaviour of glibenclamide on repeated administration to diabetic patients
- PMID: 401739
- DOI: 10.1007/BF00561783
Behaviour of glibenclamide on repeated administration to diabetic patients
Abstract
Six maturity onset diabetic patients took glibenclamide 5 mg by mouth, every morning 10 min before a standard breakfast. Serum levels of immunoreactive glibenclamide, glucose and immunoreactive insulin were measured repeatedly on the first and 15th days of treatment. Measured glibenclamide blood levels were in close agreement with an analogue computer simulation of data obtained from healthy volunteers: there was no accumulation of drug in the blood, but there was strong evidence for the existence of a slowly equilibrating "deep" compartment. Considerable insulin release and correction of the breakfast-induced hyperglycaemia were observed immediately after administration of the drug, as well as 5 h later, at lunch time. The clinical significance of blood levels of glibenclamide, as well as the correlation of pharmacokinetics with pharmacodynamics, are discussed in the light of these results.
Similar articles
-
Improved effect of glibenclamide on administration before breakfast.Eur J Clin Pharmacol. 1982;21(5):403-8. doi: 10.1007/BF00542327. Eur J Clin Pharmacol. 1982. PMID: 6804245
-
Serum glibenclamide in diabetic patients, and influence of food on the kinetics and effects of glibenclamide.Diabetologia. 1980 Jan;18(1):17-22. doi: 10.1007/BF01228296. Diabetologia. 1980. PMID: 6767639
-
Plasma levels of glibenclamide in diabetic patients during its routine clinical administration determined by a specific radioimmunoassay.Horm Metab Res. 1983 Sep;15(9):425-8. doi: 10.1055/s-2007-1018746. Horm Metab Res. 1983. PMID: 6416980
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
-
Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.Diabet Med. 1996 Sep;13(9 Suppl 6):S151-5. Diabet Med. 1996. PMID: 8894500 Review.
Cited by
-
The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs.Clin Pharmacokinet. 1987 Jun;12(6):379-401. doi: 10.2165/00003088-198712060-00001. Clin Pharmacokinet. 1987. PMID: 3301149 Review.
-
Glibenclamide-associated hypoglycaemia: a report on 57 cases.Diabetologia. 1983 Jun;24(6):412-7. doi: 10.1007/BF00257338. Diabetologia. 1983. PMID: 6411511
-
Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia.Eur J Clin Pharmacol. 2003 Jun;59(2):91-7. doi: 10.1007/s00228-003-0592-4. Epub 2003 Apr 16. Eur J Clin Pharmacol. 2003. PMID: 12698302
-
Hypoglycemia associated with the use of fluoxetine.West J Med. 1996 Mar;164(3):262-3. West J Med. 1996. PMID: 8775944 Free PMC article. No abstract available.
-
Clinical pharmacokinetic considerations in the elderly. An update.Clin Pharmacokinet. 1989 Oct;17(4):236-63. doi: 10.2165/00003088-198917040-00003. Clin Pharmacokinet. 1989. PMID: 2686883 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources